Skip to content
Screener

Theravance Biopharma TBPH Business Segments — Net Income Loss

Similar metrics at other companies

Dollar General logo
DGSingle Reportable — Net Income Loss
$444.13M+13.3%
Alumis Inc. logo
ALMSSingle Reportable — Net Income Loss
-$93.05M+6.0%
Napco Security Technologies logo
NSSCSingle Reportable — Net Income Loss
-$408K-104%
Immunome logo
IMNMSingle Reportable — Net Income Loss
-$53.84M-29.3%
ArriVent BioPharma, Inc. logo
AVBPSingle Reportable — Net Income Loss
-$43.32M+32.7%
Capricor Therapeutics logo
CAPRSingle Reportable — Net Income Loss
-$33.94M-39.2%

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$877.45M+53.9%
Enterprise value$629.86M+88.3%
P/E7.7×-36.1×
P/S+0.6×

Profitability

See full
Gross margin60.8%
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 9:00 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056760
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Interest and other income, net3,013939
Loss before income taxes(6,470)(14,138)
Provision for income tax benefit1,537559
Net loss(4,933)(13,579)
Net unrealized loss on available-for-sale investments(123)(7)
Total comprehensive loss$(5,056)$(13,586)
Net loss per share:
Net loss per share - basic and diluted$(0.10)$(0.27)

Item 1. Financial Statements (unaudited)

FAQ

What is Theravance Biopharma's business segments — net income loss?
Theravance Biopharma (TBPH) reported business segments — net income loss of -$4.93M in Q1 2026.
How has Theravance Biopharma's business segments — net income loss changed year-over-year?
Theravance Biopharma's business segments — net income loss increased by 63.7% year-over-year, from -$13.58M to -$4.93M.
What is the long-term trend for Theravance Biopharma's business segments — net income loss?
Over 2 years (2023 to 2025), Theravance Biopharma's business segments — net income loss has grown at a 38.5% compound annual growth rate (CAGR), from -$55.19M to $105.9M.
What does business segments — net income loss mean?
This represents the final bottom-line profit or loss for the segment after accounting for all operating expenses, non-operating items, and tax impacts. It is the ultimate measure of the segment's financial performance and its contribution to the overall profitability of the organization.

Ask your AI about Theravance Biopharma's business segments — net income loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude